BR112022014694A2 - Composições biofarmacêuticas e métodos relacionados - Google Patents
Composições biofarmacêuticas e métodos relacionadosInfo
- Publication number
- BR112022014694A2 BR112022014694A2 BR112022014694A BR112022014694A BR112022014694A2 BR 112022014694 A2 BR112022014694 A2 BR 112022014694A2 BR 112022014694 A BR112022014694 A BR 112022014694A BR 112022014694 A BR112022014694 A BR 112022014694A BR 112022014694 A2 BR112022014694 A2 BR 112022014694A2
- Authority
- BR
- Brazil
- Prior art keywords
- related methods
- biopharmaceutical compositions
- compositions
- biopharmaceutical
- antagonism
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949696P | 2019-12-18 | 2019-12-18 | |
| US201962950595P | 2019-12-19 | 2019-12-19 | |
| PCT/US2020/064241 WO2021126657A1 (en) | 2019-12-18 | 2020-12-10 | Biopharmaceutical compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014694A2 true BR112022014694A2 (pt) | 2022-09-06 |
Family
ID=74125707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014694A BR112022014694A2 (pt) | 2019-12-18 | 2020-12-10 | Composições biofarmacêuticas e métodos relacionados |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230059341A1 (https=) |
| EP (1) | EP4077388A1 (https=) |
| JP (2) | JP2023507981A (https=) |
| KR (1) | KR20220129548A (https=) |
| CN (1) | CN115298218A (https=) |
| AU (2) | AU2020407007A1 (https=) |
| BR (1) | BR112022014694A2 (https=) |
| CA (1) | CA3164600A1 (https=) |
| IL (1) | IL293753A (https=) |
| MX (1) | MX2022007464A (https=) |
| WO (1) | WO2021126657A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI4076385T1 (sl) * | 2019-12-20 | 2026-04-30 | Formycon Ag | Formulacije protiteles anti-pd1 |
| WO2024118587A1 (en) * | 2022-11-30 | 2024-06-06 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1-antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015017307A2 (pt) * | 2013-03-14 | 2017-11-21 | Abbvie Inc | composições de espécies com baixa acidez e métodos para produção e uso das mesmas |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| KR20180037275A (ko) * | 2015-08-24 | 2018-04-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 생물제약 조성물 |
| CN106999591B (zh) * | 2015-09-28 | 2021-02-23 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体制剂及其在医药上的应用 |
| LT3386541T (lt) * | 2015-12-07 | 2020-10-26 | Merck Patent Gmbh | Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą |
| JP2019533458A (ja) * | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
-
2020
- 2020-12-10 WO PCT/US2020/064241 patent/WO2021126657A1/en not_active Ceased
- 2020-12-10 CN CN202080094093.2A patent/CN115298218A/zh active Pending
- 2020-12-10 BR BR112022014694A patent/BR112022014694A2/pt not_active Application Discontinuation
- 2020-12-10 KR KR1020227024058A patent/KR20220129548A/ko active Pending
- 2020-12-10 EP EP20835967.9A patent/EP4077388A1/en active Pending
- 2020-12-10 MX MX2022007464A patent/MX2022007464A/es unknown
- 2020-12-10 AU AU2020407007A patent/AU2020407007A1/en not_active Abandoned
- 2020-12-10 CA CA3164600A patent/CA3164600A1/en active Pending
- 2020-12-10 IL IL293753A patent/IL293753A/en unknown
- 2020-12-10 US US17/785,506 patent/US20230059341A1/en active Pending
- 2020-12-10 JP JP2022537240A patent/JP2023507981A/ja active Pending
-
2025
- 2025-05-23 AU AU2025203823A patent/AU2025203823A1/en active Pending
- 2025-11-04 JP JP2025185522A patent/JP2026027328A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2025203823A1 (en) | 2025-06-19 |
| JP2023507981A (ja) | 2023-02-28 |
| IL293753A (en) | 2022-08-01 |
| CN115298218A (zh) | 2022-11-04 |
| EP4077388A1 (en) | 2022-10-26 |
| AU2020407007A1 (en) | 2022-06-23 |
| CA3164600A1 (en) | 2021-06-24 |
| MX2022007464A (es) | 2022-06-27 |
| WO2021126657A1 (en) | 2021-06-24 |
| JP2026027328A (ja) | 2026-02-18 |
| US20230059341A1 (en) | 2023-02-23 |
| KR20220129548A (ko) | 2022-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018016344A (es) | Miembros de union lag-3. | |
| CO2021008696A2 (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
| MX2017000985A (es) | Anticuerpos anti-pd-1. | |
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
| PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| BR112021019334A2 (pt) | Anticorpos de cadeia pesada que se ligam ao psma | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| BR112021023026A2 (pt) | Moléculas de ligação biespecíficas anti-ror1/anti-cd3 | |
| MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
| WO2021022304A3 (en) | Bispecific anti lrrc15 and cd3epsilon antibodies | |
| JOP20210323A1 (ar) | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 | |
| MA40074A (fr) | Composés liant ras multivalents | |
| MX395317B (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| EP4249515A3 (en) | Humanized or chimeric cd3 antibodies | |
| MY190324A (en) | Anti-pd-1 antibodies and compositions | |
| MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| CO2018005393A2 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos | |
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
| WO2020257289A3 (en) | Humanized antibody molecules to cd138 and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024025522-7 PROTOCOLO 870240104092 EM 06/12/2024 10:56. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11 E 13, E 25 DA LPI. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |